AI Article Synopsis
- Pertussis, a contagious respiratory illness, is still commonly reported in Canada, particularly among individuals under 15 years old; Alberta saw an incidence of 1.8 to 20.5 cases per 100,000 from 2004 to 2015.
- A study analyzed the effectiveness of pertussis vaccines using PCR tests from 2010 to 2015, focusing on individuals with defined vaccination histories and excluding those who received whole-cell vaccines.
- Results showed that vaccine effectiveness was 90% in the first year, declining to 37% after eight or more years since the last dose, indicating the need for regular boosters in adolescents and adults to maintain immunity.
Article Abstract
Background: Pertussis is still frequently reported in Canada. In Alberta, pertussis incidence ranged from 1.8 to 20.5 cases per 100,000 persons for 2004-2015. Most cases occurred in those aged <15 years. In Alberta, acellular formulations replaced whole-cell in 1997. We investigated pertussis vaccine effectiveness (VE) using a test-negative design (TND) study.
Methods: We included all persons who had a real-time PCR laboratory test for Bordetella pertussis between January 1, 2010 and August 31, 2015, in the province of Alberta, Canada. Vaccination history was obtained from Alberta's immunization repository. Vaccination status was classified as complete, incomplete, or unvaccinated, based on the province's vaccination schedule. Persons who had received ≥one dose of whole cell vaccine were excluded from analysis. Multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for pertussis infection by time since last vaccination. We adjusted for vaccination status, age, sex, neighbourhood income, urban/rural status, and the presence of a co-morbid condition. VE was calculated as [(1 - aOR) * 100].
Results: Of the 12,149 tests available, 936 (7.7%) were positive for Bordetella pertussis. Among the full cohort, VE was 90% (95% CI 87-92%) at 1 year, 81% (95% CI 77-85%) at 1-3 years, 76% (95% CI 68-82%) at 4-7 years, and 37% (95% CI 11-56%) at 8 or more years since a last dose of acellular pertussis vaccine.
Conclusions: Pertussis VE was highest in the first year after vaccination, then declined noticeably as years since a last vaccination increased. Our results suggest that a large number of adolescents and adults are susceptible to infection with Bordetella pertussis. Regular boosters throughout childhood, adolescence, and during pregnancy may be needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2019.05.067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic epidemiology and evolution of under the vaccination pressure of acellular vaccines in Beijing, China, 2020-2023.
Emerg Microbes Infect
December 2024
Beijing Chaoyang District Center for Disease Control and Prevention, Beijing 100021, China.
Pertussis (or whooping cough) has experienced a global resurgence despite widespread vaccine efforts. In China, the incidence of pertussis has rapidly increased, particularly following the COVID-19 pandemic. Whole-genome sequencing analysis was performed on 60 strains isolated in Beijing from 2020 to 2023, and the sequences were compared with those of 635 strains from China and 943 strains from other countries.
View Article and Find Full Text PDFSafety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
Lancet Glob Health
January 2025
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, London, UK; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; UK Health Security Agency, Salisbury, UK.
Background: Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses.
View Article and Find Full Text PDFEvidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
Vaccine
December 2024
Pritzker School of Law, Northwestern University, USA.
Importance: Childhood vaccination rates have declined in recent years; there is also concern that resistance to COVID-19 vaccines could spill over to childhood vaccines.
Objectives: To use local-level data to study trends in childhood vaccination rates and heterogeneity in local rates; including how many areas are below herd-immunity thresholds, and assess the association between COVID-19 vaccine hesitancy and childhood vaccination.
Design: We report, for 11 states with available data, vaccination rates for measles, mumps, rubella (MMR), and diphtheria, tetanus, acellular pertussis (DTaP) vaccines, including percentage of schools/counties with rates ≥95 %, 90-95 %, 80-90 %, and < 80 %.
Seroprevalence study reveals pertussis underreporting in Brazil and calls for adolescent/young adult boosting: mouse model demonstrates immunity restoration.
Front Immunol
December 2024
Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Background: Pertussis continues to pose a significant threat despite the availability of effective vaccines. The challenge lies in the vulnerability of infants who have not yet completed their vaccination schedule and in adolescents and adults becoming potential disease carriers.
Methods: We evaluated the seroprevalence of pertussis immunity in a cohort of 1,500 healthy Brazilian volunteers.
Pertactin deficiency of : Insights into epidemiology, and perspectives on surveillance and public health impact.
Hum Vaccin Immunother
December 2024
GSK, GSK Asia House, Singapore, Singapore.
Pertussis resurgence has been documented even in countries with high pediatric vaccine coverage. The proportion of isolates not expressing pertactin (PRN) has increased in several countries where acellular pertussis (aP) vaccines are used. We systematically reviewed published literature up to July 2023 on PRN-negative isolates in MEDLINE and Embase with no geographical limitations, complemented with a gray literature search.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!